Management of cyclical menorrhagia with prostaglandin synthetase inhibitor

Vimal Grover, V Grover, R. Usha, U Gupta, Usha Gupta, Sourav Kalra, S Kalra
Asia-Oceania journal of obstetrics and gynaecology · 1990 · vol. 16(3) , pp. 255–259 · doi:10.1111/j.1447-0756.1990.tb00235.x · PMID:2088249 · W1977517446
RCT OA: closed CC0 ⤵ 12 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

Mefenamic acid significantly reduced menstrual bleeding duration and volume in patients with unexplained cyclical menorrhagia compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A well controlled double blind prospective trial was undertaken to determine the efficacy of mefenamic acid in the treatment of menorrhagia. Eighty patients who had unexplained cyclical menorrhagia with secretory endometrium received mefenamic acid orally in a dose of 500 mg 8 hourly or a placebo tablet thrice daily starting from day-one of the cycle for 5 days or till cessation of menses. Mefenamic acid administration caused a statistically significant reduction in the number of days of bleeding from 9.7 +/- 3.1 days before treatment to 4.1 +/- 0.6 days after treatment. It also brought about significant reduction in the amount of bleeding in terms of number of pads used per day, that is from 15.2 +/- 3.1 before treatment to 6.5 +/- 0.02 after treatment. Eighty-six percent patients in the treatment group had control of menorrhagia with the drug compared to 20% in the control group without drugs and this difference was statistically significant. Mefenamic acid proved to be a potent and efficacious agent in the control of unexplained menorrhagia.

My notes (saved in your browser only)

MeSH descriptors

Mefenamic Acid Menorrhagia Adult Double-Blind Method Female Humans Mefenamic Acid Mefenamic Acid Menorrhagia Menstruation Menstruation Middle Aged Prospective Studies

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (25)

Cited by (12)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:08:04.945943+00:00
unpaywall
last seen: 2026-10-12T06:33:14.382917+00:00
License: CC0 · commercial use OK